Skip to Content

Qiagen NV QGEN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

After Strong Q1, Qiagen Maintains 2021 Outlook, as COVID-19 Tailwinds May Turn Into Headwinds Soon

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

No-moat Qiagen turned in first-quarter results that continued well above its historical growth trajectory based on strong demand for products to combat the pandemic, but the firm only maintained its outlook for the full year, suggesting current tailwinds may turn into headwinds soon. At first glance, we do not anticipate changing our fair value estimate, which includes a 2021 EPS estimate that is slightly above management's outlook range.

Read Full Analysis

Company Profile

Business Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).

Contact
Hulsterweg 82
Venlo, 5912 PL, Netherlands
T +31 773556600
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 5,700